Fast Track Designation Could Do Wonders
this other companies recently began clinical trial site recruitment for its Acclaim-1 clinical trial for treating non-small cell lung cancer. After already receiving U.S. Food and Drug Administration (FDA) Fast Track Designation in January 2020 for the trial’s patient population, the trial appears to be off to a strong start.
Additionally, Cho Research appears to be bullish on the stock. Analyst Alex Cho upgraded the stock and increased his price target from approximately $2.84 to around $8.27. Check disclaimer on my profile.